Category Archives: News

Alternative Cancer Treatment, Cancer Research, News

Some Birth Control Pills May Increase Breast Cancer Risk

Birth Control Pills
Birth Control Pills

A new study has linked certain types of birth control pills to a higher near-term risk of breast cancer, but the finding is unlikely to affect the majority of young American women.

“The study found no relationship between an increased cancer risk and the use of low-dose estrogen pills, which are currently the most commonly prescribed type of birth control pills in the U.S.,” according to a CBS News report.

High Risk Pills

The birth control pills implicated in the study are those containing moderate to high doses of estrogen. While birth control pills containing a moderate estrogen dose elevated breast cancer risk only slightly, high-estrogen medications nearly tripled breast cancer risk.

The two greatest offenders were triphasic combination pills containing norethindrone and birth control pills containing ethynodiol diacetate. If your birth control pills contain either of these ingredients, Issels Cancer Treatment Center staff urges you to talk to your doctor.

No Need to Panic

“Breast cancer is rare among young women, and there are numerous established health benefits associated with oral contraceptive use that must be considered,” study author Elisabeth Beaber of Seattle’s Fred Hutchinson Cancer Research Center told CBS News.

She recommended that women exercise caution in interpreting the study’s results, which are yet to be confirmed, and discuss their breast cancer risk with their physician. As CBS notes, some other studies have shown no appreciable link between birth control pills and increased breast cancer risk. Previous studies have shown that breast cancer risk declines when women discontinue birth control pills.

Like cancer risk, breast cancer treatment must be personalized to the unique needs of each individual. Visit our website for more information.

Alternative Cancer Treatment, Cancer Research, News

Scientists Discover Gene ‘Anchor’ Linked to Spread of Lung Cancer

The Lung Cancer Gene
The Lung Cancer Gene

One of the world’s deadliest cancers, lung cancer is the leading cause of cancer deaths in the U.S. Its ability to metastasize and quickly spread to other organs in the body is what makes lung cancer so deadly. A new genetic discovery by scientists at the Salk Institute in California may help researchers devise a way to keep lung cancer from spreading and dramatically improve the long-term outcome of this deadly form of cancer.

Cancer Cells on the Move

As described in Medical News Today, Salk researchers have discovered a gene that helps lung cancer cells “pull up their anchors in the primary tumor,” making it possible for them to move to other parts of the body to form new tumors; a process called metastasis. Normal cells have a natural adhesion that acts like an anchor, keeping the cells firmly rooted in their proper place.

Genes Linked to Cell Adhesion

Scientists already knew that cancerous cells were able to overcome this natural adhesion and travel through the bloodstream to other organs. Previous studies had even shown that some cancer cells were able to manipulate cell anchors. But the Salk Institute research is the first to link communication between specific genes to cancer cell adhesion and explain how cancer cells are able to “up anchor.” When that communication breaks down, cancer cells are set free and start traveling.

In lab and animal experiments, Salk researchers were able to re-establish communication between anchoring genes and slow metastasis. Researchers are hopeful that further research will lead to a way to stop lung cancer from spreading.

Visit our website to find out more about Issels  targeted cancer therapies.

Alternative Cancer Treatment, Immunotherapy, News

New Advances in Immunotherapy Make the News

In The News
In The News

New Advances in Immunotherapy Treatment for Cancer Targeted immunotherapy for cancer Traditional treatments for cancer take a slash ‘n burn approach, poisoning the entire body in hopes of killing off the cancer cells faster than the healthy cells. Targeted therapies that seek out and kill cancer cells while sparing all others have long been the dream of cancer researchers. Some progress towards targeted therapies has been made. For example, Herceptin and Glivec have given new hope to patients with breast cancer and leukemia.

Immunotherapy is the New “Silver Bullet” for Cancer

Using the immune system to kill cancer cells has always seemed to be a good idea. After all, the immune system’s entire purpose is to seek out diseased cells and destroy them while sparing the healthy cells. What better tool to wipe out cancer cells? Of course this raised the question of why the immune system doesn’t naturally seek out and destroy cancer cells.

The discovery of how some cancer cells manage to stop the immune system from killing them opened up a whole new way to approach cancer treatments. Many cancer cells express a protein called PD-L1 on their surfaces. When T cells (part of the immune system) attempt to kill the abnormal cancer cells the PD-L1 binds to PD-1 on the surface of the T cells. This stops the T cells from attacking the cancer cells.

Nivolumab

A drug called Nivolumab that blocks the interaction of PD-1 with tumor-expressed PD-L1 is the first of the drugs targeting this pathway to make it to the market. In clinical trials Nivolumab has extended the lifespan of patients with advanced melanoma. Without Nivolumab most patients with advanced melanoma don’t survive for a year after diagnosis but with Nivolumab 63% were alive a year later, and even more remarkable 43% were alive two years later.

Nivolumab is only the first of many treatments that will “unmask” tumor cells to the immune system, allowing the immune system to do what it does best- target and kill diseased cells. Other companies have drugs in development targeting the PD-1 pathway.

Immune system unmasking drugs will join cancer vaccines and other therapies intended to use the immune system to fight cancer naturally. Issels Integrative Oncology has been offering individualized immunotherapy for over 60 years to cancer victims.

Cancer Research, News

Cancer News Roundup for July

The Latest In Cancer Treatment
The Latest In Cancer Treatment

The latest in cancer treatment news for July:

  • Rogue cancer cells in blood could help explain how tumors evolve as genes change over time, leading to new cancer treatments.
  • Study finds faulty process in muscle-invasive bladder cancer, pointing to EGRF targeting drugs as possible cancer treatment.
  • The National Cancer Research Institute points to the need for age limits in clinical trials to be more flexible to allow teenage cancer patients greater access to new treatments.
  • Genetic research identifies three rare pathogenic mutations not previously known in public gene sequencing databases known to predispose carriers to breast and Lynch syndrome spectrum cancers.
  • A new research report shows antihistamines used to treat colds, allergies and insect bites may play a role in warding off tumors.
  • Study shows men over 50 who cycle more than nine hours a week are more likely to develop prostate cancer.

Looking for more information on cancer treatment specific to yourself or a loved one? Contact Issels today. Issels offers the latest and most effective alternative cancer therapies available.

Immunotherapy, News

Immunotherapy In The News

In The News
In The News

Immunotherapy for cancer – the use of a patient’s own antibodies to create cancer-blocking properties – has been called everything from the disease’s potential “off-switch” to the “beginning of the end of chemotherapy.”

In recent immunotherapy news, Israel-based Compugen announced in July what it calls a milestone in cancer immunotherapy collaboration. Working with Bayer HealthCare, Compugen aims to develop and commercialize “therapeutic antibodies against two checkpoint protein candidates discovered by Compugen,” as the company’s website puts it.

“We are very pleased by the achievement of this initial drug development milestone for one of the two programs in our collaboration with Bayer,” said Compugen President and CEO Dr. Anat Cohen Dayag. “After investing more than a decade of extensive multidisciplinary research in establishing our broadly applicable predictive discovery infrastructure, we selected the area of checkpoint-based cancer immunotherapy as our first focused discovery effort.  Therefore, it is extremely satisfying to see our growing competitive position, in terms of both advancement of our therapeutic programs in immuno-oncology and continuing discoveries of novel targets in this exciting area, which is increasingly being viewed as a potential major breakthrough in cancer treatment.”

More immunotherapy news
On July 13, Business Standard reported that an immunotherapy treatment had been developed to treat cancer in dogs. “Scientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna discovered that a receptor frequently found on human tumour cells (epidermal growth factor receptor or EGFR) is nearly 100 per cent identical with the EGF receptor in dogs,” as the Press Trust noted. Scientists noted that “due to the high similarity of the receptor in humans and dogs, this type of therapy should work well in dogs too.”

Cancer Research, News

Google Ventures and Big Data on Cancer

Big Cancer Data
Big Cancer Data

Google Ventures has recently made a large investment into Flatiron Health Inc., a medical software company whose cancer patient data is used to help doctors make cancer treatment decisions. The $100-plus million investment reportedly enabled the company to purchase another software firm, Altos Solutions, which compiles oncology data and whose electronic medical records are cloud-based.

A plethora of alternative cancer treatment information – soon to be accessible via the cloud.
Flatiron’s software compiles a wide array of data, including clinical and genomic data, information on patient outcomes, notes from doctors, billing, and more for the use of oncologists. Compiled with Altos’ treatment data and cloud accessibility, this information will give doctors wider access to clinical trial information including past cancer treatments and outcomes which would have otherwise been difficult to access.

An investment in hope…
Bill Maris, managing partner with Google Ventures, stated they typically don’t make investments of this size unless they really believe in the team, the product, and the good it can do for the world. The acquisition of Altos by Flatiron is very complementary, offering a significant step forward in cancer care.

Google Ventures also investing in other medical data software companies.
Other Google Venture investments include DNAnexus, Inc., who is building the world’s first searchable archive of DNA information, as well as Foundation Medicine, with its tumor analyzing software, and Predilytics Inc., which tracks hospital discharges and re-admissions.

This combination of healthcare and internet technology offers an elegant solution for patient care, and with the help of Google Ventures, a clearer view of cancer patient needs and treatment options appears to be on the horizon.